Silvant Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Silvant Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15,237	Closed	-$1.74M	–	339
2020 Q3	$1.74M	Sell	15,237 -4,095	-21%	-$442K	0.33%	78
2020 Q2	$2.17M	Sell	19,332 -1,298	-6%	-$138K	0.39%	72
2020 Q1	$1.85M	Sell	20,630 -404	-2%	-$39.6K	0.4%	70
2019 Q4	$2.27M	Sell	21,034 -323	-2%	-$34.5K	0.41%	72
2019 Q3	$2.09M	Sell	21,357 -2,716	-11%	-$306K	0.41%	68
2019 Q2	$3.15M	Sell	24,073 -2,251	-9%	-$290K	0.56%	54
2019 Q1	$3.56M	Sell	26,324 -1,078	-4%	-$134K	0.64%	48
2018 Q4	$2.67M	Sell	27,402 -795	-3%	-$94K	0.53%	59
2018 Q3	$3.92M	Sell	28,197 -4,481	-14%	-$562K	0.48%	76
2018 Q2	$4.06M	Sell	32,678 -376	-1%	-$43.9K	0.5%	75
2018 Q1	$3.68M	Buy	+33,054	New	+$3.95M	0.47%	78

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Silvant Capital Management's ALXN Position: Q4 2020 in Review

Silvant Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 15,237 shares — an estimated $1.74M sold.

Silvant Capital Management first reported a position in ALXN in Q1 2018 and held it in 11 quarters. The position peaked at $4.06M in Q2 2018. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Silvant Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Silvant Capital Management sold 15,237 Alexion Pharmaceuticals shares in Q4 2020, an estimated $1.74M.
Silvant Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 11 quarters.
Silvant Capital Management's Alexion Pharmaceuticals position peaked at $4.06M in Q2 2018.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Silvant Capital Management's 13F filing for Q4 2020, filed 5 Feb 2021.